Resistance to fluoroquinolones has emerged in different Streptococcus spp. (4, 5, 8, 15) , mainly due to efflux or mutations in the quinolone resistance-determining regions (QRDR) of the genes coding for type II topoisomerase enzymes: DNA gyrase (gyrA/gyrB) and topoisomerase IV (parC/parE) (7) . Recently, Biedenbach et al. showed that fluoroquinolone resistant GBS (FR-GBS) were identified in the USA in 1997; however in the western Pacific region in Japan it was detected in the year 2002 (1, 8) .
Although ciprofloxacin has been available since 1990, and levofloxacin was introduced in 2000 in Taiwan, none of the studies reported the presence of fluoroquinolone resistance in GBS isolates from 1990 to 2007 (6) . The objective of this study was to: 1) determine the prevalence of fluoroquinolone resistance, 2) to characterize the QRDR mutations, and 3) to determine the clonal relation among resistant isolates by pulsed-field gel electrophoresis (PFGE). Clinical isolates were stored in Todd-Hewitt medium (Difco Laboratories, Detroit, MI) with 15% glycerol at -70°C until further testing. Antibiotic susceptibilities were performed by disk diffusion for the following antibiotics: ampicillin, cefazolin, clindamycin, erythromycin, gentamicin, levofloxacin, penicillin and vancomycin (2) .
Minimum inhibitory concentration (MIC) was determined by agar dilution method for levofloxacin (MIC breakpoint ≥8 µg/ml) and other fluoroquinolones, including
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from moxifloxacin, gatifloxacin, trovafloxacin, garenoxacin, and ciprofloxacin (3). PCR amplification and DNA sequencing of QRDR regions responsible for the fluoroquinolone-resistant phenotype were performed as described previously (1, 14) .
PFGE of SmaI-digested genomic DNA samples was carried out with a contour-clamped homogeneous electric field system (CHEF Mapper XA; Bio-Rad Laboratories, Hercules, CA) according to the instruction manual. PFGE banding patterns were interpreted as described previously (13) .
Of the 1,994 GBS isolates, 26 (1.3 %) isolates were resistant to levofloxacin. The MIC of levofloxacin resistant (LR) GBS isolates was found to be ≧16 µg/ml. Since mutations in the QRDR leads to cross resistance to fluoroquinolones, we determined the MICs by the agar dilution method and found that all the LR-GBS isolates had elevation in MICs to ciprofloxacin (MIC, 32-64 µg/ml), garenoxacin (MIC, 2-4 µg/ml), gatifloxacin (MIC, 4-8 µg/ml), moxifloxacin (MIC, 2-4 µg/ml), and trovafloxacin (MIC, 8-16 µg/ml) ( Table 1 pattern test showed that all the FR-GBS isolates were totally susceptible to penicillin, ampicillin, vancomycin, and cefazolin. Resistance to gentamicin was found in 100% of isolates, followed by erythromycin (65%) and clindamycin (62%).
gyrA, parC and parE triple mutations were identified in all the FR-GBS isolates (Table 1) . In gyrA, a Ser-81-to-Leu (Ser81Leu) mutation was predominant, while in gyrB mutations were absent. But in parC, a Ser79Tyr mutation was present in 16 isolates and
on November 3, 2017 by guest http://aac.asm.org/ Downloaded from 10 isolates had a Ser79Phe mutation. In parE, all the isolates had a unique Ile495Leu mutation. Isolates with the parE mutation also had gyrA (Ser81Leu) and parC (Ser79Phe) mutations predominantly. To determine the clonal relation of isolates resistant to fluoroquinolones, we performed PFGE. Among the 26 resistant isolates, 17 pulsed types (A to Q) were identified (Fig. 1, Table 1 ).
In Taiwan In GBS, QRDR mutations have been reported previously in gyrA and parC only. High level resistance could be linked to the presence of a triple mutation (gyrAparC-parE) in each isolate. Mutations in gyrA occurred predominantly at amino acid position 81 (Ser-81-to-Leu) and in parC at Ser79Tyr and Ser79Phe, which were similar to earlier reports (1, 9, 14) . The QRDR of gyrA is the primary target which mediates fluoroquinolone resistance in several gram negative bacteria, while in gram positive bacteria parC is the primary target, which substantially increases the probability of a second mutation in gyrA, resulting in high level fluoroquinolone resistance (4, 7, 10) .
Based on our data we were unable to determine whether gyrase or topoisomerase IV is the primary target for fluoroquinolones or the other antibiotic(s) associated with the triple
on November 3, 2017 by guest http://aac.asm.org/ Downloaded from mutations. Further analysis of the minor targets gyrB and parE, revealed that mutations were absent in gyrB in FR-GBS isolates, similar to the previous reports on fluoroquinolone resistance in GBS (1, 8, 14) . A unique mutation (Ile495Leu) was present in parE, but since gyrB and parC mutations were also present in the isolates with the parE mutation, its significance is unknown. It can be either a silent mutation or a mutation similar to a S. pneumoniae parE (Ile-460-Val) variant that led to reduced susceptibility to fluoroquinolones (9) . Presence of 17 pulsed types and absence of a predominant pulsed type indicates that the fluoroquinolone resistant isolates are genetically unrelated. Spread of FR due to single and multiple clones was observed in other S. pneumoniae and S. pyogenes isolates (5, 11). In GBS, Wehbeh et al., suggested the nosocomial spread of levofloxacin resistant GBS isolates based on two major clusters identified by PFGE (14) .
Since all the FR-GBS isolates were totally susceptible to ampicillin, penicillin, cefazolin and vancomycin, these antibiotics remain the preferred choice to treat GBS infections empirically. Since resistance to fluoroquinolones can develop during therapy and cross-resistance to other fluoroquinolones is likely to occur, when prescribing fluoroquinolones for GBS infections susceptibility testing and monitoring during therapy should be done to avoid treatment failure (5, 10) . Continuous molecular level surveillance is needed to prevent further dissemination of FR-GBS clones in Taiwan.
In conclusion, our study confirmed the emergence of genetically unrelated FR- 
